Form 4: Fortress Biotech CFO David Jin Reports Acquisition of Shares Under Employee Stock Purchase Plan

David Jin, CFO of Fortress Biotech, reports acquiring 2,625 shares of common stock at $1.2283 per share under the company's Employee Stock Purchase Plan.

Summary

• David Jin, the Chief Financial Officer of Fortress Biotech, reported a transaction on October 1, 2024.
• He acquired 2,625 shares of Fortress Biotech common stock at a price of $1.2283 per share.
• The acquisition was made under the Issuer's Employee Stock Purchase Plan.
• Following the transaction, Jin directly owns 240,893 shares, including 230,000 shares underlying deferred restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction report. The CFO's participation in the employee stock purchase plan is a mildly positive signal, but not significantly impactful.

Positives

• The CFO's participation in the Employee Stock Purchase Plan could be viewed positively, indicating confidence in the company's future.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders. This particular filing reflects the CFO's participation in the company's employee stock purchase plan.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders, primarily providing transparency to shareholders regarding insider transactions.

Key Dates